AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Royalty Pharma plc Director's Dealing 2025

May 9, 2025

30286_dirs_2025-05-09_2737ab1a-542e-4970-beae-38e6f0001767.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2025-05-08

Reporting Person: Lloyd George W. (EVP, Investments & CLO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-08	Class A Ordinary Shares	A	48646	—	Acquired	48646	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Ordinary Shares	3000	Direct
Class A Ordinary Shares	273960	Indirect
Class A Ordinary Shares	495860	Indirect
Class A Ordinary Shares	220000	Indirect
Class A Ordinary Shares	52000	Indirect
Class A Ordinary Shares	28000	Indirect
Class A Ordinary Shares	4011.19	Indirect

Footnotes

F1: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.